Managing new-onset type 1 diabetes during the COVID-19 pandemic: challenges and opportunities
Garg SK, Rodbard D, Hirsch IB, Forlenza GP
Diabetes Technol Ther. Pub. online 17 April 2020
Leggi
Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials
Ghosh-Swaby OR, Goodman SG, Leiter LA, et al.
Lancet Diabet Endocrinol. 2020;8(5):418-35
Leggi
The association of ambient fine particulate matter exposure during pregnancy with blood glucose levels and gestational diabetes mellitus risk: a prospective cohort study in Wuhan, China
Ye B, Zhong C, Li Q, et al.
Am J Epidemiol. Pub. online 14 April 2020
Leggi
Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial
Yamada Y, Katagiri H, Hamamoto Y, et al.
Lancet Diabet Endocrinol. 2020;8(5):377-91
Leggi
Impact of diabetes on colorectal cancer stage and mortality risk: a population-based cohort study
Qiang JK, Sutradhar R, Giannakeas V, et al.
Diabetologia. 2020;63:944-53
Leggi
Preserved C-peptide secretion is associated with fewer low-glucose events and lower glucose variability on flash glucose monitoring in adults with type 1 diabetes
Gibb FW, McKnight JA, Clarke C, Strachan MWJ
Diabetologia. 2020;63:906-14
Leggi
Glucose-dependent insulinotropic peptide and risk of cardiovascular events and mortality: a prospective study
Jujić A, Atabaki-Pasdar N, Nilsson PM, et al.
Diabetologia. 2020;63:1043-54
Leggi
Diabetes is a risk factor for the progression and prognosis of COVID-19
Guo W, Li M, Dong Y, et al.
Diabetes Metab Res Rev. Pub. online 31 March 2020
Leggi
Association between preoperative metformin exposure and postoperative outcomes in adults with type 2 diabetes
Reitz KM, Marroquin OC, Zenati MS, et al.
JAMA Surg. Pub. online 8 April 2020
Leggi